To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).
Has the ability to understand and willingness to sign a written ICF before the performance of any study-specific procedures on this protocol and 2022-0515
Age ≥ 18 years
Has locally advanced or metastatic RCC with predominantly clear cell subtype
Has at least one measurable lesion as defined by RECIST version 1.1
Has received treatment with any frontline systemic therapy for metastatic RCC
Has a history of leptomeningeal disease or spinal cord compression
Has a history of autoimmune disease requiring active therapy
Patients may be enrolled if they have treated brain metastases with no evidence of progression or hemorrhage after therapy for brain metastases (e.g. radiation therapy, surgery, radiosurgery) AND
M.D. Anderson Cancer Center
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Collaborator
United States Department of Defense
Collaborator